Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399957 · ClinicalTrials.gov registry record
Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients
A clinical trial, sponsored by Mount Sinai Rehabilitation Hospital.
- Completed
- Registry status
- 52
- Enrollment target
NCT01399957 is a clinical trial that has completed, run by Mount Sinai Rehabilitation Hospital. The registered enrollment target is 52 participants.
The verdict
NCT01399957 has completed, sponsored by Mount Sinai Rehabilitation Hospital.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399957
The ClinicalTrials.gov registry entry for NCT01399957 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mount Sinai Rehabilitation Hospital, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01399957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399957 about?
NCT01399957 is a clinical study titled "Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients". Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staf...
What is the current status of trial NCT01399957?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2010-08. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01399957?
This trial is sponsored by Mount Sinai Rehabilitation Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.